CRESCENT BIOPHARMA, INC.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | – | $-0.74 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | After market close | $1.00M | $-0.70 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $10.80M | $-4.01 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | $-1.27 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Jun 18, 2025 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 3, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 2, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 3, 2023 | Before market open | – | – | – |
Press releases
Announcements Crescent Biopharma filed with the SEC
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Other events · EX-99.1 to Form 8-K
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Other events · EX-99.2 to Form 8-K
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
SEIZE THE MOMENT for a brighter future CRESCENT BIOPHARMA STRATEGIC PARTNERSHIP & PIPELINE UPDATE DECEMBER 4, 2025 NASDAQ: CBIO
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Crescent Biopharma Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Crescent Biopharma Reports Second Quarter 2025 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Crescent Biopharma Completes Closing of Merger
Material agreement · Acquisition or disposition completed · Results of operations · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
thousands except share and per share amounts)
Material agreement · Acquisition or disposition completed · Results of operations · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Material agreement · Acquisition or disposition completed · Results of operations · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
January 2025 Crescent Biopharma Overview
Regulation FD disclosure · EX-99.1 to Form 8-K
November 2024 Crescent Biopharma Overview
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
enters into acquisition agreement with Crescent Biopharma
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CONFIDENTIAL October 2024 Crescent Biopharma Confidential Overview
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in
Regulation FD disclosure · EX-99.1 to Form 8-K
Results of Pivotal Phase 3 Trial of
Regulation FD disclosure · EX-99.2 to Form 8-K
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 2024 | NASDAQ: GLYC
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
Results of operations · EX-99.1 to Form 8-K
March 2024 | NASDAQ: GLYC
Regulation FD disclosure · EX-99.1 to Form 8-K
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
Results of operations · EX-99.1 to Form 8-K
© 2021 GlycoMimetics, Inc. All rights reserved.
Regulation FD disclosure · EX-99.1 to Form 8-K
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
©2021 GlycoMimetics, Inc. All rights reserved.
Regulation FD disclosure · EX-99.1 to Form 8-K
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022
Results of operations · EX-99.1 to Form 8-K
GlycoMimetics Reports Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
GlycoMimetics Reports Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K